Journal Publication

SYHX2011 shows longer PFS than albumin-bound paclitaxel in advanced breast cancer

A 459-patient phase III trial found a 2-month progression-free survival edge for the reformulated taxane, while overall survival remained immature at 25 months of follow-up.

Updated survival analysis from a randomized, double-blind phase III trial reported a median progression-free survival of 7.6 months for SYHX2011 versus 5.6 months for albumin-bound paclitaxel in advanced breast cancer.

By AppliedXLJuly 22, 2026

Executive Summary

A reformulated albumin-bound paclitaxel extended progression-free survival compared with the approved reference product in a randomized phase III trial of advanced breast cancer, with the difference reaching statistical significance after extended follow-up.
Overall survival trended in the same direction but has not reached a mature, statistically definitive result, leaving the survival benefit unconfirmed even as the progression-free survival signal holds up.
The new formulation was built to simplify preparation and reduce skin-related toxicity by replacing most of the albumin carrier with mannitol and sucrose, a manufacturing change rather than a new mechanism of action.
Consistent directional trends across hormone receptor-positive, triple-negative, and both first-line and later-line subgroups support continued evaluation, though these subgroup reads are descriptive and not independently powered.

The finding

Updated survival results from a phase III trial of SYHX2011, a novel albumin-bound paclitaxel formulation, showed a median progression-free survival (PFS) of 7.6 months compared with 5.6 months for the approved albumin-bound paclitaxel product Keaili, in patients with unresectable locally advanced or metastatic breast cancer. The difference reached statistical significance, with a p-value of 0.028 and a hazard ratio of 0.79 (95% CI: 0.63-1.01). SYHX2011 replaces most of the non-particulate human serum albumin carrier used in the reference formulation with mannitol and sucrose, a change intended to simplify drug preparation and reduce skin rash rather than alter the paclitaxel mechanism itself. Updated

How it was done

The trial randomized 459 patients 1:1 to SYHX2011 or the reference albumin-bound paclitaxel in a multicenter, double-blind design. At a data cutoff of December 29, 2025, median follow-up reached 25.2 months in the SYHX2011 arm and 25.0 months in the comparator arm. The analysis reported median PFS, median overall survival (OS), and hazard ratios with 95% confidence intervals for both endpoints, along with descriptive subgroup breakdowns by hormone receptor status, triple-negative status, and line of therapy. Updated

The survival question

Median overall survival was not reached in the SYHX2011 arm and was 24.3 months in the comparator arm, a hazard ratio of 0.84 with a 95% confidence interval of 0.64 to 1.11 that crosses 1 and carries a p-value of 0.11. That places the PFS result and the OS trend in different positions: PFS cleared conventional statistical significance, while OS moved in the same direction without yet doing so. The trial's authors describe the OS data as immature at this follow-up point. Updated

Subgroup pattern

Directional trends toward longer PFS and OS with SYHX2011 appeared across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Consistency across these strata, spanning different tumor biology and treatment settings, adds some weight to the overall PFS finding, though the abstract itself flags that subgroup results require cautious interpretation given the descriptive, non-prespecified nature of that analysis. Updated

What it changes

For a reformulated version of an already-approved chemotherapy backbone, the relevant bar is whether the new formulation preserves or improves on the established efficacy and tolerability of the reference product, not whether it introduces a new treatment paradigm. The reported PFS advantage, combined with a directionally consistent but immature OS trend, supports continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option in this setting, as the study's own authors conclude. Updated

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.